Title: Phase III Randomized Study of Cyclophosphamide(Drug information on cyclophosphamide), Doxorubicin(Drug information on doxorubicin),
Vincristine, and Prednisone(Drug information on prednisone) (CHOP) With or Without Either Rituximab(Drug information on rituximab) or Iodine(Drug information on iodine) I
131 Tositumomab (Monoclonal Antibody Anti-B1) in Patients With Newly Diagnosed
Follicular Non-Hodgkin's Lymphoma
Protocol Number: CLB-50102, SWOG-S0016
Participating Institutions: Southwest Oncology Group, Southwest Oncology
Group CCOP Ordering Group
Contact: Marjorie Godfrey, Coordinator, San Antonio, Texas, (210)
677-8808; for a complete listing of
study contacts, click here
Latest Information: http://www.cancer.gov/clinical_trials/
Title: Phase III Study of Early High-Dose Chemoradiotherapy and
Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients
with Intermediate or High Grade Non-Hodgkin's Lymphoma
Protocol Number: CAN-NCIC-LY11, CLB-59903, E-S9704, SWOG-S9704
Participating Institutions: Southwest Oncology Group, Cancer and Leukemia
Group B, Eastern Cooperative Oncology Group, National Cancer Institute of Canada
Contact: Marjorie Godfrey, Coordinator, San Antonio, Texas, (210)
677-8808; for a complete listing of
study contacts, click here
Latest Information: http://www.cancer.gov/clinical_trials/
Phase II
Title: Pilot Study of Idiotype Vaccine and Epoch-Rituximab Chemotherapy
in Untreated Mantle Cell Lymphoma
Protocol Number: 1033
Participating Institution: National Cancer Institute Medicine Branch
Contact: Wyndham H. Wilson, MD, Bethesda, Maryland, (301) 435-2415,
wilsonw@mail.nih.gov
Title: Phase II Study of Rituximab and High-Intensity Chemotherapy
With Filgrastim(Drug information on filgrastim) (G-CSF) Support in Patients With Previously Untreated Burkitt's
Lymphoma or Burkitt's Leukemia
Protocol Number: CLB-10002
Participating Institution: Cancer and Leukemia Group B
Contact: CALGB Central Office, Chicago, Illinois, (773) 702-9171
Latest Information: http://www.cancer.gov/clinical_trials/
Title: Phase II Study of Rituximab, Doxorubicin, Etoposide(Drug information on etoposide),
Vincristine, Prednisone, and Cyclophosphamide in Patients With Previously
Untreated Aggressive CD20+ B-Cell Non-Hodgkin's Lymphoma
Protocol Number: CLB-50103
Participating Institution: Cancer and Leukemia Group B
Contact: CALGB Central Office, Chicago, Illinois, (773) 702-9171; for a complete listing of
study contacts, click here
Latest Information: http://www.cancer.gov/clinical_trials/
Title: Phase II Study of Intensive Chemotherapy and Rituximab With
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Mantle
Cell Lymphoma
Protocol Number: CLB-59909
Participating Institution: Cancer and Leukemia Group B
Contact: CALGB Central Office, Chicago, Illinois, (773) 702-9171; for a complete listing of
study contacts, click here
Latest Information: http://www.cancer.gov/clinical_trials/
Title: Phase II Randomized Study of Rituximab With or Without
Interleukin-12 in Patients With B-Cell Non-Hodgkin's Lymphoma
Protocol Number: NCCTG-N0087
Participating Institution: North Central Cancer Treatment Group
Contact: Stephen M. Ansell, MD, Rochester, Minnesota, (507) 284-2511,
ansell.stephen@mayo.edu; for a complete listing of
study contacts, click here
Latest Information: http://www.cancer.gov/clinical_trials/
Title: Phase II Study of High Dose Cytarabine(Drug information on cytarabine)/Methotrexate and High
Dose Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine (HCVAD) in Patients
with Newly Diagnosed Diffuse and Nodular Mantle Cell Lymphoma
Protocol Number: MDA-DM-97200, NCI-T97-0101
Participating Institution: M. D. Anderson Cancer Center
Contact: Jorge E. Romaguera, MD, Houston, Texas, (713) 792-2933
Latest Information: http://www.cancer.gov/clinical_trials/
A 52-year-old man presented with an erythematous lesion in the axilla of unknown duration. Surgical excision was performed. What is your diagnosis?
